Startups
Octave Bioscience
Octave Bioscience is a Menlo Park, California precision-neurology company founded in 2014. It develops blood-based biomarker tests and analytical tools for neurodegenerative disease, beginning with multiple sclerosis. Its commercially available MS Disease Activity (MSDA) Test uses a panel of proteins and data models to provide clinicians with objective measures of disease activity. It is developing tests for MS progression and Parkinson’s disease; Parkinson’s research is supported by the Michael J. Fox Foundation. Doug Biehn is president and CEO, and founder William Hagstrom chairs the board. Disclosed financing includes USD2.5 million seed funding, USD14 million Series A in 2018, USD32 million Series B in 2020, an undisclosed strategic investment from Merck Global Health Innovation Fund in 2021, a USD30 million Series B extension in 2023 and USD35.6 million Series C equity financing in 2025. A separate USD15.5 million SVB term-loan agreement was announced with the Series C. Research grants and the loan commitment are distinguished from equity proceeds.
Founded 2014
Team
 Brook ByersBoard Director |
 Darin OkudaSenior Medical Advisor |
 David BrazelVice President, Data Science |
 Debbie LedetChief Access Officer |
 Doug BiehnPresident, Chief Executive Officer · Board Director |
 Erika B. OrtizDirector of People Operations |
 George ScangosBoard Director |
 Grant Heidrich IIIBoard Director |
 Jennifer GravesConsultant Senior Medical Director |
 Jennifer MellumVice President, Marketing |
 Kirk StockwoodSenior Vice President, Commercial |
 Lucy CoassinBoard Director |
 Marcel KonradChief Financial Officer |
 Terrie LivingstonVice President, Medical Affairs |
 Tom HawesBoard Director |
 William HagstromChairman of the Board · Founder |
 Zachary FernandesVice President, Business Development |